Identification of Resistance Mechanisms to Evaluate Therapeutic Options for Refractory Yolk-Sac Tumors Using Multikinase Inhibitors or Antibody (CLDN6)-/ Nanobody (Cxcr4)-Drug-conjugates
European Urology(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要